It is well known that survival of patients with advanced squamous-cell carcinoma of the head and neck (SCCHN) has not significantly improved despite recent advances in radiation and chemotherapy treatment. Specifically, a very low objective response rate can be obtained in patients with recurrent SC
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid
✍ Scribed by J. Atzpodien; H. Kirchner; S. Duensing; E. Lopez Hänninen; A. Franzke; J. Buer; M. Probst; P. Anton; H. Poliwoda
- Publisher
- Springer-Verlag
- Year
- 1995
- Tongue
- English
- Weight
- 353 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive
## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin
## Abstract ## Background. We have previously conducted phase II trials with a combination of 13‐__cis__‐retinoic acid (13‐cRA), interferon‐α2a (IFN‐α2a), and α‐tocopherol (α‐TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings